LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results